Summit Therapeutics reported updated overall survival (OS) data for its drug ivonescimab, showing an improved trend with a hazard ratio of 0.76 in the HARMONi trial. This positive development strengthens the drug's profile ahead of its PDUFA goal action date in November 2026, potentially increasing the likelihood of FDA approval.
Summit Therapeutics announced updated overall survival (OS) data from its Phase III HARMONi trial for ivonescimab, showing an improved hazard ratio of 0.76, consistent across Asian and Western patients. This is significant because while the primary OS analysis initially showed a positive trend but wasn't statistically significant, the extended follow-up has strengthened the data, making it more compelling for FDA review. This positive trend increases the probability of regulatory approval for ivonescimab, which is a major catalyst for Summit Therapeutics. Short-term, this could lead to increased investor confidence and a potential stock price rally for SMMT. Long-term, successful approval would open up a new revenue stream for the company in the non-small cell lung cancer market. The key opportunity for traders is the potential upside if the FDA approves the drug based on this increasingly robust data.